Table 1.
Patient Demographics and Clinical Characteristics
| Baseline Characteristics | Number of Patients (32) | Percentage (%) |
|---|---|---|
| Age (years) | ||
| Median | 45 | |
| Range | 15–69 | |
| Sex | ||
| Male | 17 | 53 |
| Female | 15 | 47 |
| ECOG performance status | ||
| 0 | 14 | 44 |
| 1 | 17 | 53 |
| 2 | 1 | 3 |
| Histology | ||
| UPS | 6 | 19 |
| LPS | 4 | 12 |
| LMS | 6 | 19 |
| SS | 4 | 12 |
| FS | 2 | 6 |
| ERMS | 5 | 16 |
| PNET/ES | 3 | 10 |
| AS | 2 | 6 |
| Treatment lines of anlotinib combination therapy | ||
| First line | 8 | 25 |
| Second line | 12 | 37.5 |
| Third line | 12 | 37.5 |
| Anlotinib dose | ||
| 12 mg | 29 | 91 |
| 10 mg | 3 | 9 |
| Radiotherapy history | ||
| Yes | 12 | 38 |
| No | 20 | 62 |
| Surgery history | ||
| Yes | 30 | 94 |
| No | 2 | 6 |
| Chemotherapy history | ||
| Yes | 26 | 81 |
| No | 6 | 19 |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.